Reduced risk of reoperation after treatment of femoral neck fractures with total hip arthroplasty

Figures & data

Figure 1. Flow chart of included procedures.

Table 1. Patient demographics and outcome

	Unmatched patients					Matched patients					Patients unable to match^a
	HA		THA		p-value	HA		THA		p-value
Sample size, n	8,237		3,016			2,902		2,902			114
Demographics
Age, mean (SD), years	84	(6.8)	74	(8.1)	< 0.001	74	(8.2)	75	(7.8)	0.2	64	(5.4)
Female, n (%)	5,692	(69)	2,116	(70)	0.3	1,971	(68)	2,037	(70)	0.07	79	(69)
Male, n (%)	2,545	(31)	900	(30)		931	(32)	865	(30)		35	(31)
BMI, mean (SD)	23.6	(3.9)	24.4	(4.1)	< 0.001	24.4	(4.1)	24.4	(4.1)	1.0	25	(3.4)
ASA classification, n (%)					< 0.001					0.4
1	219	(2.7)	337	(11)		232	(8.0)	255	(8.8)		82	(72)
2	3,068	(37)	1,620	(54)		1,554	(54)	1,588	(55)		32	(28)
3	4,401	(53)	1,012	(34)		1,067	(37)	1,012	(35)		0	0
4	549	(6.7)	47	(1.6)		49	(1.7)	47	(1.6)		0	0
Survival status
Deceased, n (%)	3,867	(47)	589	(20)	< 0.001	1,054	(36)	578	(20)	< 0.001	11	(10)
Time to death, mean (SD), years	2.1	(1.5)	2.8	(1.5)	< 0.001	2.5	(1.6)	2.8	(1.5)	< 0.001	3.1	(1.6)
Revisions, n (%)	298	(3.6)	92	(3.1)	0.2	167	(5.8)	86	(3.0)	< 0.001	6	(5)
Time to revision, mean (SD), years	3.1	(1.5)	3.1	(1.5)	0.1	3.0	(1.5)	3.1	(1.5)	0.5	3.0	(1.6)
Reoperations, n (%)	369	(4.5)	124	(4.1)	0.4	192	(6.6)	117	(4.0)	< 0.001	7	(6)
Time to reoperation, mean (SD), years	3.0	(1.5)	3.1	(1.5)	0.2	3.1	(1.5)	3.1	(1.5)	0.6	3.3	(1.6)

a All patients treated with THA.

Figure 2. Kaplan–Meier survival curve (95% CI) with revision as end-point.

Figure 3. Kaplan–Meier survival curve (95% CI) with reoperation as end-point.

Figure 4. Kaplan–Meier survival curve (95% CI) with death as end-point.

Table 2. Risk of revision and reoperation with death as competing risk, unmatched patients. Absolute risk reduction (95% CI)

	Revision		Death
THA	0.51	(0.37–0.71)	0.59	(0.54–0.65)
Age	0.97	(0.95–0.98)	1.03	(1.02–1.03)
Female	0.81	(0.65–1.0)	0.69	(0.66–0.72)
ASA 2	0.93	(0.54–1.6)	1.7	(1.3–2.2)
ASA 3	1.01	(0.58–1.8)	2.6	(2.0–3.3)
ASA 4	0.99	(0.50–2.0)	3.5	(2.7–4.5)
BMI	1.01	(0.98–1.04)	0.96	(0.95–0.96)
	Reoperation		Death
THA	0.63	(0.48–0.84)	0.58	(0.53–0.64)
Age	0.97	(0.96–0.99)	1.03	(1.02–1.03)
Female	0.82	(0.67–1.01)	0.69	(0.66–0.73)
ASA 2	1.2	(0.73–2.0)	1.7	(1.3–2.2)
ASA 3	1.3	(0.79–2.2)	2.5	(2.0–3.2)
ASA 4	1.2	(0.66–2.3)	3.5	(2.7–4.5)
BMI	1.02	(1.0–1.05)	0.96	(0.95–0.96)

Table 3. Risk of revision and reoperation with death as competing risk, matched patients. Absolute risk reduction (95% CI)

	Revision		Death
THA	0.51	(0.37–0.71)	0.59	(0.54–0.65)
	Reoperation		Death
THA	0.63	(0.48–0.84)	0.58	(0.53–0.64)